Fate Therapeutics, Inc. (NASDAQ:FATE) Quarterly Basic Net EPS At 2016-03-31

0

For the year ended 2016-03-31 Fate Therapeutics, Inc. (NASDAQ:FATE) basic consolidated EPS came $-1.1769. Conversely, for the quarter ended 2016-03-31, it was $-1.1769.

EPS can be simply called as a fraction of profits that is disbursed against each outstanding share. It is measured using the formula – net profit/outstanding shares. The element ‘Per-share earnings’ is majorly utilized by market experts to give earnings and price projections. Suppose a group “S” announces a net profit of $15,000 in a given year. The count of outstanding shares is 300. So, its EPS will be $50. EPS is issued every quarter, indicating the stakeholders can evaluate the financial performance periodically.

EPS alone cannot indicate on the financial well-being of a firm. For a clear picture, it is vital to look into the price to earnings ratio of company.

EPS from continuing operations

Fate Therapeutics, Inc. (NASDAQ:FATE) EPS from continuing operations was $-1.1769 for the fiscal ended 2016-03-31. For the quarter ended 2016-03-31, this figure was $-1.1769.

EPS contribution from parent

Fate Therapeutics, Inc. (NASDAQ:FATE) confirmed basic EPS of $-1.1769 for the year ended 2016-03-31 from its parent group. Conversely, for the quarter closed 2016-03-31 it was $-1.1769.

Basic net EPS

Fate Therapeutics, Inc. (NASDAQ:FATE) basic net EPS was $-0.29 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it came at $-0.29.

Consolidated diluted EPS

Fate Therapeutics, Inc. (NASDAQ:FATE) consolidated diluted EPS was -1.1769 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it stood at $-1.1769.

Basic diluted EPS

Fate Therapeutics, Inc. (NASDAQ:FATE) basic diluted EPS was $-0.2911 for the quarter ended 2016-03-31. For the year ended 2016-03-31, basic diluted EPS was $-0.2911.

Net diluted EPS

Fate Therapeutics, Inc. (NASDAQ:FATE) posted net diluted EPS of $-1.18 for the fiscal closed 2016-03-31. For the quarter ended 2016-03-31, net diluted EPS was $-1.18.

Diluted EPS from parent

Fate Therapeutics, Inc. (NASDAQ:FATE) diluted EPS from parent group was $-1.1769 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it stood at $-1.1769.

Fate Therapeutics, Inc. (NASDAQ:FATE) net basic EPS was $-1.27 for the year ended 2016-03-31. For the quarter ended 2016-03-31, it was $-1.27.

For the year ended 2016-03-31, basic shares outstanding were 20.452 while for the quarter ended 2016-03-31 is 20.452.

For the fiscal ended 2016-03-31, the diluted outstanding shares were 20.452 and for the quarter ended 2016-03-31 it was 20.452.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 7 times, 1 visits today)